HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ana Cláudia Camargo Miranda Selected Research

111In-DTPA-trastuzumab

1/2021Anti-HER2 monoclonal antibody based-radioimmunoconjugates: Assessment of the chelating agent influence.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ana Cláudia Camargo Miranda Research Topics

Disease

1Neoplasms (Cancer)
01/2021
1Prostatic Neoplasms (Prostate Cancer)
02/2020
1Brain Injuries (Brain Injury)
06/2018

Drug/Important Bio-Agent (IBA)

1Immunoconjugates (Immunoconjugate)IBA
01/2021
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2021
1human ERBB2 proteinIBA
01/2021
1111In-DTPA-trastuzumabIBA
01/2021
1Chelating AgentsIBA
01/2021
1Pentetic Acid (DTPA)FDA LinkGeneric
01/2021
1LigandsIBA
02/2020
1AntigensIBA
02/2020
1gallium 68 PSMA-11IBA
02/2020
1Dihydrotachysterol (AT 10)IBA
06/2018